-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

JP Morgan Maintains Neutral on NovoCure, Raises Price Target to $99

Benzinga · 01/06/2023 11:07
JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $86 to $99.